UBS maintained Johnson & Johnson (NYSE:JNJ) at Buy with a $180 per share price target on Friday in its analyst day preview note. The firm said it expects the company to reiterate its pharma...
- Day's Range
- 155.47 - 156.81
- 52 wk Range
- 144.95 - 181.04
- Prev. Close
- Average Vol.(3m)
- 1-Year Change
- Market Cap
- P/E Ratio
- United States
- Shares Outstanding
- Dividend (Yield)
- 4.76 (3.08%)
- Next Earnings Date
- Jan 23, 2024
(Updated - December 1, 2023 6:42 AM EST)UBS analysts upgraded Johnson & Johnson (NYSE:JNJ) from Neutral to Buy with a price target of $180.00 (from $167.00).The analysts commented, "Led by...
Johnson & Johnson (NYSE:JNJ) MedTech, the company’s medical device business, announced today it finalized the acquisition of Laminar, a private medical device company specializing in...
Berkshire Hathaway (NYSE:BRKa), led by renowned investor Warren Buffett, has made significant changes to its stock portfolio, as revealed in its third-quarter earnings report. The...
Berkshire Hathaway Inc . (NYSE:BRKa), the conglomerate led by Warren Buffett, has made significant changes to its investment portfolio, according to recent SEC filings. The company has...
NEW YORK - Bristol Myers (NYSE:BMY) Squibb Co. (NYSE:BMY) experienced a downturn on Thursday, ending a two-day streak of gains as its shares dropped 1.42% to close at $50.84. The decline...
NEW YORK - Investors are preparing for the upcoming ex-dividend date on Monday, when Johnson & Johnson (NYSE:JNJ), STERIS plc (NYSE:STE), and Prudential Financial Inc (NYSE:NYSE:PRU) will...
The Greek Development Ministry has imposed fines on the local subsidiaries of two major U.S. firms, Johnson & Johnson (NYSE:JNJ) Hellas and Colgate-Palmolive (NYSE:CL) Hellas. The companies...
Investing.com -- U.S. stock futures inch up on Wednesday, after the main indices on Wall Street soared in the prior session on optimism that slower-than-projected inflation data may lead the...
An analyst from Stifel maintained J&J (NYSE: JNJ) at 'hold' with a price target of $155.00 from a prior price target of $170.00. Prior to this rating, J&J had 9 buy ratings, 13...
Johnson & Johnson (NYSE:JNJ)'s MedTech unit is planning to seek FDA clearance for its Ottava robotic surgical system in 2024, following delays caused by technical issues and disruptions from...
Despite a year of declining stock prices, Johnson & Johnson (NYSE:JNJ) and Altria Group (NYSE:NYSE:MO) continue to offer high-yield dividends backed by strong business fundamentals,...
Pfizer Inc. (NYSE:PFE)'s shares experienced a marginal increase of 0.03% to $30.56 on Tuesday, marking the second day of consecutive gains in a favorable market environment. The S&P...
In a significant development, GSK has acquired an exclusive license for JNJ-3989, a siRNA therapeutic targeting hepatitis B, in a $1 billion agreement. The deal entails the initiation of a...
British pharmaceutical firm GSK has secured a $1 billion deal with Janssen, a Johnson & Johnson subsidiary, for the exclusive rights to further develop and commercialize the latter's...
Berkshire Hathaway (NYSE:BRKa)'s subsidiary, New England Asset Management (NEAM), has recently increased its investments in Coca-Cola (NYSE:KO), U.S. Bancorp, and Johnson & Johnson...
Merck & Co . (NYSE:MRK) saw a reversal in its recent winning streak on Tuesday, with shares falling 0.31% to close at $103.03, in stark contrast to the overall positive tone of the market....
Johnson & Johnson (JNJ) (the Company) announced today that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company on October 20, 2023, that she is...
Johnson & Johnson (JNJ) declared a quarterly dividend of $1.19 per share, or $4.76 annualized. The dividend will be payable on December 5, 2023, to stockholders of record on November 21,...
An analyst from Barclays maintained J&J (NYSE: JNJ) at 'equalweight' with a price target of $165.00 from a prior price target of $162.00. Prior to this rating, J&J had 9 buy...
An analyst from Morgan Stanley maintained J&J (NYSE: JNJ) at 'equalweight' with a price target of $171.00 from a prior price target of $174.00. Prior to this rating, J&J had 9 buy...
An analyst from Raymond James maintained J&J (NYSE: JNJ) at 'outperform' with a price target of $172.00 from a prior price target of $179.00. Prior to this rating, J&J had 9 buy...
By Stephen Culp NEW YORK (Reuters) - The Nasdaq dipped and benchmark U.S. Treasury yields surged on Tuesday as robust economic data and strong third-quarter earnings suggested the Federal...
The U.S. retail sector saw an unexpected surge in September, with Retail Sales figures increasing by a higher-than-expected +0.7% month over month. This rise is up from August's upwardly...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.